Apogee Therapeutics, Inc. (APGE), a clinical-stage biotechnology company, announced Wednesday positive 16-week data from Part B of the Phase 2 APEX clinical trial of zumilokibart (APG777), a potential best-in-class anti-IL-13 antibody, in patients with moderate-to-severe AD.
The trial met all its primary and secondary endpoints with high statistical significance including 65.9% of patients treated with mid-dose zumilokibart achieving EASI-75 (41.9% placebo adjusted).
Based on these dose optimization results and subject to regulatory interactions, Apogee plans to move forward with the mid-dose, which achieved the best clinical activity of the three doses tested and was well-tolerated, in its Phase 3 trials in the second half of 2026.
The company also announced a $1.3 billion Strategic financing collaboration with Blackstone Life Sciences that is expected to provide funding through commercialization of zumilokibart in AD, asthma, and EoE.
In Wednesday's pre-market trading, TGT is trading on the NYSE at $53.76, up $2.52 or 4.93 percent.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.